Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Update

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the target of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 29,926 shares, an increase of 49.7% from the July 15th total of 19,996 shares. Based on an average trading volume of 45,467 shares, the short-interest ratio is presently 0.7 days. Currently, 0.5% of the shares of the company are sold short.

Redhill Biopharma Stock Up 5.9%

Redhill Biopharma stock opened at $0.63 on Thursday. The firm has a market cap of $3.82 million, a price-to-earnings ratio of 0.00 and a beta of 5.00. Redhill Biopharma has a 52 week low of $0.57 and a 52 week high of $2.79. The business’s 50-day moving average price is $0.72 and its 200 day moving average price is $0.86.

Institutional Investors Weigh In On Redhill Biopharma

A hedge fund recently raised its stake in Redhill Biopharma stock. Gagnon Securities LLC grew its position in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) by 383.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,102 shares of the biotechnology company’s stock after purchasing an additional 68,280 shares during the quarter. Gagnon Securities LLC owned approximately 1.68% of Redhill Biopharma worth $89,000 as of its most recent SEC filing. 7.20% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Redhill Biopharma in a report on Monday, August 3rd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.